Andrew Astley

About Andrew Astley

Global asset management leader with an outstanding track record of revenue growth, strategic product placement, global operating platform development and new business entry across institutional and wealth channels. Builder of successful businesses in ETFs, alternatives, ESG, defined contribution / retirment income and multi-asset solutions. Motivated business leader with a future-focused approach. Ability to adapt to an increasingly competitive global and complex commercial landscapes. Passion for the intersection between intellectual challenge, client demand, and commercial outcomes.Global Expertise: Deep understanding of localized client needs in a global context. Targeted product development, marketing, pricing, and vehicles for local/regional demand. Established regional and local teams supported by global “follow the sun” platform including significant leverage of Bangalore captive. Established EMEA COO function at SSGA.Strategist: Serial developer of new approaches, teams, and strategies to maximize commercial impact. Recruited in late 2016 to create T. Rowe Price’s first product team. Established SSGA’s EMEA COO function in 2006. Proposed and developed SSGA’s Product organization. Grew the combined global Product and Marketing team to 250 professionals. Commercial Growth: Led complex SSGA initiatives and commercial opportunities, including acquisition and integration of SSGA’s first liquid alternatives capability as well as company’s only large-scale ($110B) purchase of GE Asset Management. Established and approved pricing at both vehicle and client/deal levels balancing profitability and commercial viability. Early stage use of quantitative modeling to customize client solutions leading to $30M net new revenue over five years. Risk Mitigation and Execution: Led post financial crisis securities lending illiquidity efforts retaining nearly 100% of clients impacted. Established systematic product development, management and seed capital management processes to address specific client needs while ensure regulatory, legal, operational and risk feasibility.

Experience

1. Partner & COO

   Rubik Therapeutics

   Jun 2024 — Present · Cambridge, MA, US

   Rubik Therapeutics is on a mission to change the treatment paradigm for solid tumors by developing cell therapies that target highly selective, unique targets and by leveraging insights into immune cells signaling to counteract immune suppression

Education

• University of Michigan

  BA, Political Science

  1988 — 1992

Skills

• Investments
• Sales
• Sales Management
• Mutual Funds
• Fixed Income
• Product Development
• Hedge Funds
• Alternative Investments
• Asset Management
• Equities
• Business Development
• Marketing
• Leadership
• Finance
• Financial Services
• Crm